Alprazolam and DN-2327 (Pazinaclone) in Humans: Psychomotor, Memory, Subjective, and Reinforcing Effects

Geoffrey K. Mumford, Craig R. Rush, Roland R. Griffiths

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The psychomotor, memory, subjective, and reinforcing effects of DN-2327 (DN), a novel partial agonist at benzodiazepine receptors, were compared with those of alprazolam (AL) in 14 men with histories of sedative drug abuse. Placebo, DN (8, 16, and 32 mg), and AL (0.5, 1.0, and 2.0 mg) were administered orally in a randomized, double-blind, cross-over design. DN and AL produced similar maximal impairment on psychomotor and memory performance. AL produced greater increases in participant ratings of sedation and a variety of somatic symptoms that were absent following DN. Abuse liability measures showed both drugs increased liking and good effects and were categorized by participants as sedative-hypnotics; however, 2 of 3 indirect and 1 direct measure of drug reinforcement were greater with AL than with DN. The dissociation between psychomotor-memory performance effects and various subjective effects demonstrates a novel pharmacological profile of DN.

Original languageEnglish (US)
Pages (from-to)39-48
Number of pages10
JournalExperimental and clinical psychopharmacology
Issue number1
StatePublished - Feb 1995

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Alprazolam and DN-2327 (Pazinaclone) in Humans: Psychomotor, Memory, Subjective, and Reinforcing Effects'. Together they form a unique fingerprint.

Cite this